Transaction details
Allison C. Hoffman, who serves as General Counsel and Secretary of Phreesia, Inc. (NASDAQ: PHR), sold 6,176 shares of the company’s common stock on April 20, 2026, according to a Securities and Exchange Commission filing disclosed after the trade. The shares changed hands at $9.06 per share, producing gross proceeds of $55,954.
The filing notes the sale was carried out pursuant to a Rule 10b5-1 trading plan that Hoffman established on December 19, 2025. The use of a prearranged 10b5-1 plan indicates the transaction followed an established schedule or formula set up before the date of sale.
Post-sale ownership and stock performance
After completing the April 20 sale, Hoffman directly holds 157,309 shares of Phreesia common stock. The SEC filing does not indicate any other transactions beyond the sale recorded on that date.
Phreesia’s shares have moved substantially in recent months. Over the past six months the stock has fallen 59%. More recently the share price has shown a short-term rebound, rising 9.7% in the last week.
Analytic perspective cited in filing
The filing references analysis from InvestingPro indicating the stock appears undervalued at current levels and noting the company maintained profitability over the last twelve months. The reference points readers to InvestingPro for a Fair Value analysis and additional ProTips, including 14 supplementary items.
Quarterly results and guidance revision
Phreesia reported fourth-quarter fiscal 2026 revenue of $127.1 million, marginally above the Street estimate of $126.6 million. The company also posted adjusted EBITDA of $29.4 million, exceeding the consensus estimate of $28.1 million.
Despite the quarter’s modest beats, Phreesia lowered its fiscal 2027 revenue guidance by about 7%. The company attributed the reduction to disruptions in its Network Solutions pharmaceutical advertising market, which it said are affecting revenue expectations for the coming fiscal year.
Analyst responses
The guidance reduction prompted a range of analyst reactions. Raymond James and BMO Capital each cut their price targets to $16 and $14 respectively while retaining Outperform ratings. Citizens adjusted its stance by downgrading the stock to Market Perform from Market Outperform, despite Phreesia posting non-GAAP earnings per share of $0.33, a result that beat expectations.
Meanwhile, KeyBanc kept its Overweight rating and retained a $28 price target in the face of the lower revenue outlook. DA Davidson reduced its price target to $14 from $30 but maintained a Buy rating. These mixed responses illustrate varying interpretations among brokerage analysts about the company’s outlook following the guidance change.
Context and closing
The insider sale, reported under an existing 10b5-1 plan, coincides with a period of softening near-term revenue expectations for Phreesia even as recent quarterly figures modestly exceeded estimates. The combination of a sizeable six-month share-price decline and short-term uptick, along with divergent analyst actions, highlights the current debate among market participants over valuation and near-term operational headwinds tied to advertising commitments in the Network Solutions segment.